Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02835222 · ClinicalTrials.gov registry record · Phase 2
Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients
A Phase 2 study of Untreated Adult Acute Myeloid Leukemia, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 2
- Study locations
NCT02835222: Active Phase 2 study of Untreated Adult Acute Myeloid Leukemia, sponsored by Wake Forest University Health Sciences.
NCT02835222 is a Phase 2 study of Untreated Adult Acute Myeloid Leukemia that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 57 participants, below the 104-participant average among 12 other Untreated Adult Acute Myeloid Leukemia trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02835222, a Phase 2 study of Untreated Adult Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 2
- Study locations
Study Summary
This pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and daunorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selinexor with induction, consolidation, and maintenance therapy may kill more cancer cells in older patients with acute myeloid leukemia.
Primary Outcome
Kaplan-Meier estimation will be used to analyze the overall survival. Overall survival (OS) is measured from the date of randomization to the date of death due to any cause. Participants will be monitored for survival through routine follow-up visits.
Conditions Studied
Interventions
- DRUG Selinexor
- DRUG Cytarabine
- DRUG Daunorubicin Hydrochloride
Study Locations (2)
North Carolina
- Comprehensive Cancer Center of Wake Forest University - Winston-Salem
Virginia
- Virginia Commonwealth University Massey Cancer Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2018-02-02 |
| Est. Completion | 2027-02-26 |
| Phase | Phase 2 |
What the registry record for NCT02835222 still lists
NCT02835222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 104-participant average among 12 other Untreated Adult Acute Myeloid Leukemia trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Untreated Adult Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Selinexor is the first listed.
NCT02835222 reports a single indexed study location in North Carolina, Virginia.
Frequently Asked Questions
What is clinical trial NCT02835222 about?
NCT02835222 is a clinical study titled "Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients". This pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs use...
What is the current status of trial NCT02835222?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2018-02-02. Estimated completion is 2027-02-26.
What conditions does trial NCT02835222 study?
This clinical trial studies the following conditions: Untreated Adult Acute Myeloid Leukemia.
What interventions are being tested in trial NCT02835222?
The interventions under investigation include: Selinexor (DRUG), Cytarabine (DRUG), Daunorubicin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02835222?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02835222 being conducted?
This trial has 2 study locations across North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Untreated Adult Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02835222's enrollment target sits among peer trials
57 4th of 12 higher than 9 of 12 other Untreated Adult Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Untreated Adult Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
RECRUITING · Phase 2
-
Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia
COMPLETED · Phase 2
-
PXD101 in Treating Patients With Acute Myeloid Leukemia
COMPLETED · Phase 2
-
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
COMPLETED · Phase 2
-
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
COMPLETED · Phase 2
-
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI